FitEx for Endometrial Cancer Survivors: Initial Efficacy
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Endometrial Cancer
Related studies linked through entity extraction aliases.
DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer
- Status
- RECRUITING
- Phase
- N/A
Endometrial Changes in Breast Cancer Women.
- Status
- UNKNOWN
- Phase
- N/A
Staging Endometrial caNcer Based on molEcular ClAssification
- Status
- UNKNOWN
- Phase
- N/A
Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools
- Status
- RECRUITING
- Phase
- N/A
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Status
- RECRUITING
- Phase
- PHASE2
A Cohort Study of Uterine Malignancies
- Status
- RECRUITING
- Phase
- N/A
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.
- Status
- RECRUITING
- Phase
- N/A
Genetic Testing in African Americans
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer
- Status
- COMPLETED
- Phase
- N/A
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
- Status
- RECRUITING
- Phase
- PHASE1